Comparative Pharmacology
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
EPINASTINE HYDROCHLORIDE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category A/B
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer